Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Sweden
Finland
Denmark
Norway
Latest
Trending
Followed

BioArctic, Audiocast, Q1'26

By Inderes5/20/2026, 7:30 AM
BioArctic

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Gunilla Osswald
00:00 - 11:56

Good morning and welcome to my presentation for the first quarter of 2026. It has been a strong start of the year for BioArctic following a transformative year of 2025 with record financial results. It shows that the growth era continues in a great way for BioArctic. It's reassuring to see that more and more patients are getting access to Leqembi, and we had more than €500 million of sales during our last 12 months, and that resulted in a commercial milestone to BioArctic. Our projects and our BrainTransporter technology are also progressing really well, and we have increased focus on business development, which is based on great interest in BrainTransporter and in our projects. I'll talk more about that in today's presentation. Next slide please. BioArctic is listed on Nasdaq Stockholm, Large Cap. This is our disclaimer. Next slide please. So I'm Gunilla Osswald and I'm the CEO of BioArctic. And I will share today's presentation with our CFO Anders Martin-Löf and our Chief R&D Officer Johanna Fälting and our Chief Commercial Officer Graham Block. Next slide please. I will start our presentation by giving some key highlights. Next slide please. BioArctic is focusing on two different platforms in precision neurology. And we are among the world-leading innovators in both areas. The first area is about creating highly selective antibodies, which target aggregated, misfolded forms of toxic proteins. The most advanced program here is Lecanemab. Lecanemab, and we also have projects targeting alpha synuclein, TDP-43 and huntingtin. The second area involves utilizing our BrainTransporter Platform in unique ways to deliver antibodies more efficiently into the brain. But we have now also broadened our scope, and we are also working on other modalities like enzymes and genetic medicine and small molecules to enable more efficient transportation of them also into the brain with innovative approaches. The innovations at BioArctic continue to impress me deeply. They are unique and very competitive. Next slide please. We are already delivering on our 2030 ambitions that we presented at our Capital Markets Day last year, and we have stated that we have four areas of focus. The first one is to establish Leqembi as a disease modifying treatment for Alzheimer's disease. And here we see a steady growth across geographies with sales that were more than €500 million in the last 12 months, and we expect the subcutaneous auto-injector for Leqembi, together with increasing use of blood-based biomarkers, to contribute to continued strong growth. The second aspect here is that Eisai has also indicated in the guidance for 2026, that we are expecting sales of more than €900 million. So I think that Leqembi is well on its way to become a blockbuster, with yearly sales more than 1 billion USD in not too long. The second area is to have a broader pipeline and more advanced projects in all stages of development. And I'm happy to see that our pipeline has expanded last year and our projects are progressing really well. I want to highlight our α-synuclein project, where the Phase II study is fully recruited, with the results expected later this year, and also the follow-up compound BAN2238 with our BrainTransporter coupled to an α-synuclein antibody. And there the IND activities are ongoing in order to take the compound into the clinic next year. The third area focuses more on partnerships. Last year, we initiated partnerships with Bristol Myers Squibb and Novartis. And we're very pleased with both of those partnerships and really impressed with how the collaborations are progressing and delivering. We also see continued strong interest in both our projects and our BrainTransporter platform. Partnership discussions are complex and take time. We are in a very strong position with our high-quality projects and innovative technologies. The fourth aspect is strong financials, and our quarterly royalty revenues from Leqembi sales grew 68% compared to the first quarter last year. And we have now more than 2 billion Swedish crowns in cash, which means that we can continue to invest in our projects and our innovations. And we have also the possibility to start paying some dividends. Next slide please. Our business model is built around partnerships, which is a key component behind our success. Eisai has been a long-term successful collaboration all the way back since 2005. And now we are getting 9% royalties from global Leqembi sales. And we are just then past our second commercial milestone and got another €20 million from Eisai, and we have €34 million still remaining in milestones for Bristol-Myers Squibb. We have received 100 million USD so far, and there is a substantial amount left and Novartis. We have so far received 30 million USD. And also here is a substantial amount still to receive if it also continues well. We are grateful for Novartis, from whom we received 30 million USD, which helped us build the company and also to progress the project further. And it's a project I strongly believe in, and we're looking forward to more results, and we expect more partnerships to come. That is our business model, and we're working on that, and we cannot say exactly when that will be, but we will let you know when we can disclose more. Next slide please. So by that, I hand over to our Chief R&D Officer, Johanna Fälting. Thank you, Gunilla. Next slide, please. So, as Gunilla talked about, our R&D portfolio is built on two platforms: Antibodies and the BrainTransporter platform, providing both depth and scalability in neurodegenerative diseases. We combine fully funded partnerships with leading pharma such as Eisai, BMS and Novartis. With proprietary programs that offer further out-licensing potential, progress in the portfolio remains strong. All BrainTransporter collaborations are on track, and key milestones have been reached for our internal programs, including the start of R&D enabling activities for BAN2238 and BAN3014. Overall, we are advancing a diverse, partner-validated pipeline with growing scientific, strategic and commercial options. Next slide please. So our alpha-synuclein portfolio continues to advance and expand. Offering multiple opportunities across alpha synuclein programs. Our lead program is progressing well. The phase two Exidavnemab study in Parkinson's Disease. And Multiple System Atrophy is now fully recruited. And we have held key regulatory and key opinion leader interactions to prepare for the next stage of development. Next generation assets in the portfolio are progressing as well, with BAN2238 in IND-enabling phase and BAN2278 in discovery. This builds a strong and expanding alpha synuclein pipeline from clinical stage to future innovation. Next slide please. So, our BrainTransporter Platform addresses one of the most fundamental challenges in neuroscience: efficient delivery of therapeutics across the blood-brain barrier. And this is enabled by active transport of biopharmaceuticals into the brain via the transferrin receptor. And this enhanced delivery can translate into higher, faster and deeper brain exposure with improved clinical outcomes, good patient convenience, safety, and lower cost for manufacturing. The BrainTransporter therefore plays a critical role in unlocking the full potential of CNS therapies. Next slide please. Our next-generation alpha-synuclein antibody BAN2238 demonstrates strong preclinical performance, both with enhanced brain exposure and a favorable safety profile. So by combining the alpha-synuclein targeting with our BrainTransporter technology, BAN2238 achieved a significant increase in brain exposure in preclinical models. And that is what you see in the middle picture here. And importantly, this enhanced delivery is achieved without compromising safety. We observe no signs of anemia or reduction of reticulocytes while maintaining its full effective function. And that's the data shown to the right. Reduction in reticulocytes is a commonly reported side effect targeting the transferrin receptor for brain delivery. So overall, BAN2238 highlights how the BrainTransporter has the potential to both improve target engagement and reduce development risk. Strengthening the value of our next-generation pipeline. Next slide please. So, as Gunilla also mentioned, we are now broadening our BrainTransporter platform beyond antibodies and enzymes to also include additional modalities such as genetic medicines and small molecules. Significantly increasing the scope of the platform. The data in the picture here. Clearly shows how the brain transporter coupled modalities deliver superior brain distribution. Compared to a standard therapy. In the top picture you see a standard therapy. And in the lower pictures in green you see an antibody. In yellow, you see an enzyme. And in red you see a small modality. And all of them have very, very much higher brain exposure when coupled to the BrainTransporter Platform. So across the platform, delivery of antibodies are preclinically validated, and enzymes are advancing with our first internal program. So overall, the brain transporter is evolving into a versatile platform with both current and future value drivers across CNS discovery disorders. So overall, the BrainTransporter platform is evolving into a versatile platform with both current and future value drivers across CNS disorders. Next slide please. So then I will hand over to our chief commercial officer Oskar Bosson. Thank you, Johanna. I will continue.

Oskar Bosson
11:56 - 18:13

An update on Leqembi. And I'll start by stating that the global sales of Leqembi amounted to around 580 million USD in Eisai's fiscal year 2025. So that is almost a doubling versus the previous fiscal year. And we can see good growth across the board. And Leqembi continues to be the global market leader of the anti-amyloid antibodies. A couple of the driving factors are that the market for blood biomarker continues to grow. And there has been approximately a 12-fold increase over the last two years, with the number actually doubling every six months since January 2024. Last year, CMS also formally included the blood-based biomarkers as an Aβ confirmatory diagnosis, and today it is estimated that approximately 15% of diagnoses were done by these blood-based biomarkers, and these will continue to increase as more tests are expected to be approved this year. Another factor is that more and more patients receive continued treatment after the Leqembi maintenance dosing was approved first for the IV and then for the subcutaneous formulation. The auto-injector I-click, which was approved in August last year. And according to Eisai, the auto-injector also seems to have led to an increase in new patients initiating treatment with Leqembi IV. So going forward, we see even more expansion possibilities with the potential approval of the subcutaneous initiation treatment, both in the US with the PDUFA date of August 4th, and with an expected approval also in Japan in Q3 this year and in China in Q1 next year. So this is a huge advantage for patients, the caregivers, and less of a bottleneck for hospitals. And obviously also a competitive edge for Leqembi. So in Europe, the IV maintenance dosing is under regulatory review at EMA since February. And, in parallel, the negotiations for pricing and reimbursements are ongoing in the EU. And so today it's available in Germany and Austria, as well as out-of-pocket in the UK, Finland and Portugal. So next slide please. So as the Nordic countries are BioArctic's home market, I thought I would also comment on the recent negative recommendation for Leqembi by the NT-council in Sweden. As we have seen in other European countries, it is a challenge to get immediate access, and we knew that the dialogue would be challenging. Also in Sweden, based on the assessment report issued in December last year by the TLV, the Dental and Pharmaceutical Benefits Agency. In which some of the assumptions in the health economic modelling were extremely conservative in our opinion. Although Eisai was very solution oriented in the negotiations, the expectations from the New Therapies Council were impossible to meet at this point. But both Eisai and BioArctic, we are very committed to securing patient access in Sweden and across Nordics. And the NT-council has stated that there is a possibility to reopen the dialogue. For example, if and when we have the IV maintenance dosing approved by EMA, and we could also try to find other innovative ways of securing the structured introduction. We are also evaluating a resubmission in Denmark, and in the coming months, we are expecting to see assessment reports coming out of Norway and Finland. But in the meantime, we see that there is a private market in Finland where clinics have now started Leqembi treatment, and we are approached by other private clinics across the Nordics who are looking into this possibility as well. So in parallel, our neuroscience account managers as well as our medical affairs team are working every day with educational and site readiness activities in preparation for a broader reimbursement across the Nordics. Next slide, please. So finally, I would like to conclude by showing a few highlights from the ADP Congress in March in Copenhagen, where four-year follow-up data were presented for the EU approved population, meaning the ApoE for non-carriers or heterozygotes. This data show that long-term continuation of treatment is essential, and that four years of treatment can save between 10 to 14 months in the mid-stage of the disease. Also, as usage increases across the world, more and more hospitals present real-world data from clinical practice at these congresses, specifically at ADP, from countries such as the US, Japan, China, and South Korea. Also, as usage increases across the world, more and more hospitals present real-world data from clinical practice in these Congresses at ADP, specifically from countries such as the US, Japan, China, and South Korea. And to the right, you can see, for example, the graph showing that there is also high treatment persistence in initially 371 patients at a US clinic starting in 2023, with 78% at 18 months. And after two years, it was a 67% persistence of the treatment. So more and more data further strengthen Lecanemab's efficacy and safety profile, and we are already looking forward to attending the next Congress, coming up at the AAIC in London in July. So next slide, and I will thereby hand over to our CFO, Anders Martin-Löf.

Anders Martin-Löf
18:14 - 25:22

Thank you. And I'll start by commenting a little bit on the Leqembi sales. And as already mentioned, we were really happy to see that the full yearly Leqembi sales exceeded €500 million, as that triggered a sales milestone payment to us of €20 million. If we look at the quarter, the global Q1 sales were ¥26.2 billion, roughly $168 million. That's a 27% increase from the last quarter. And that meant that our royalties grew by 27% to 160.8 million Swedish Kronor. That was quite a steep increase, as you can see in the graph, up from 127 million in the fourth quarter. And this really big boost is due to the fact that the China sales are now back on normal levels after very low sales in Q3 and Q4 due to stockpiling during the second quarter of 2025. So China sales were now ¥4.1 billion, or $27 million, and that's almost a tenfold increase from the fourth quarter. Our largest market is the US market. The growth is largely driven by the simplified diagnosis with blood-based biomarkers and the introduction of these. That was a very healthy growth, going up to ¥13.4 billion, i.e. $86 million. And that's a 13% increase from the fourth quarter. And I also alluded to that Eisai is expecting this growth to continue as the blood-based biomarkers are really starting to make an impact on the market. And of course, when it comes out later this year for induction therapy, that should mean a further boost. Japan is the second largest market. And they have really built a strong network between the primary and specialty care sectors. There we saw a solid growth, but it's still affected by a price reduction that was introduced in November last year, but it's still chugging along really well, and we're also expecting the subcutaneous version to be approved there later this year in the third quarter. We also touched on the EU launch already. It's good to see that it's starting to happen, but that's still a very low share of our royalties from Q2 to the full year figures. The highlight here is that it was good to see that Eisai's forecast for 2025 was ¥76.5 billion. They beat that by 15%, reaching ¥88 billion, or roughly $580 million. So they roughly doubled from 24 to 25. Last week, they also issued a new forecast for 2026 of ¥143.5 billion. That's roughly $910 million. So, as Gunilla said, they are now approaching blockbuster status with Leqembi. Which is really reassuring for us. A significant part of that drug growth is expected to come from the US market. As you can see here, the Americas sector is expected to grow from ¥44.6 billion to ¥77.5 billion. So that's roughly a 74% increase, which is significantly higher than they are expecting for the global market. So a lot of growth is expected to come from the US with the Lecanemab-based biomarker really making a splash from the second half of this year. If this forecast holds true, we will receive roughly ¥880 million in royalties during the same period, i.e. From April 26th to March 2027, which is, of course, a significant amount for us. Turning to the next slide, we see on the left-hand side our net revenues. Our Q1 revenues were 438 million Swedish. That's quite a big decline from the first quarter last year. But you should remember that we recorded a $100 million upfront from Bristol Myers Squibb in the first quarter last year, and we cannot repeat that every first quarter. Still, we're really happy about the revenues we generated. And that includes those. This was 290 million Swedish kronor. That was a milestone payment from Eisai. We're also really happy to see that the recurring revenue continues to increase. So the royalty was 161 million and the promotion revenue is 7 million. We also recorded 51 million Swedish from the Novartis collaboration, where we received a $30 million upfront payment last year that is recognized over the entire collaboration. Turning then to our expenses. It seems like they're fairly flat; our operating expenses in the quarter were 207 million, compared to 203 million in the first quarter last year. However, last year we had quite a big currency effect that was recorded as a cost. So if you look at the underlying operating costs, they are actually increasing quite a lot to 203 this year versus 131 last year. And we do expect to see a continued increase in the cost for this year compared to 2025. I have previously guided that we expect the cost for 2026 to be roughly 50 to 70% higher than 2025. We don't expect that high growth in the cost. Currently, we would like to revise that to be roughly 40 to 60% higher in 2026 compared to 2025. On the right hand side, you see our operating profit. We're really happy. We made a profit of 211 million Swedish Crowns, which is lower than last year. But that's still very, very solid. And we expect to be profitable for the full year in 2026. Finally, on the last slide, you see our net result. This was very much in line with our operating profit, where the financial net was positive, and then a tax of over 12 million counteracted that. So all in all, very much in line with the operating profit, cash flow then, of course, significantly lower than our operating profit. That's due to the fact that the sales milestone from Eisai was not paid in the quarter (it will be received during the second quarter), but our cash balance was over 2 billion Swedish crowns. So again, very, very solid position. And we can continue to invest for the long term in our portfolios. So we look forward to continued investments and continued growth of the company. With that, I hand back to Gunilla.

Gunilla Osswald
25:23 - 28:32

Thank you so much. We're coming towards the end of today's presentation with some upcoming news and some closing remarks. So if we look at the second quarter coming forward, we see that more and more patients are getting access to Leqembi around the globe, which is really reassuring. And we also see that in the Nordics so far through several private clinics in Finland. And we expect to see further progress in the Nordics initially on the private market, as Eisai is driving continued regulatory processes on Leqembi in a great way. And Leqembi subcutaneous auto-injector is approved for maintenance dose in the US, and we're now awaiting the response at the latest by 24th of August for induction treatment as well. And later this year, in the third quarter, we expect a response from the authorities in Japan for both initiation and maintenance dosing of the subcutaneous auto injector, and a response for China early next year. We are, as Anna said, also looking forward to more presentations on Leqembi at the next big Alzheimer Congress in July in London at AAIC. And we are also looking forward to Exidavnemab phase three readout that Johanna talked about in both Parkinson's disease and Multiple System Atrophy later this year. And we're also looking forward to when we can disclose additional partnerships. Next slide please. So, some key takeaways from today's presentation. I think BioArctic continues in the growth era in an excellent way. And we see great progress both on Leqembi, as well as the rest of our portfolio and the BrainTransporter technology; we are already delivering on our 2030 ambitions. So I think Leqembi is well on track to become an established treatment for Alzheimer's disease, and sales continue to show increasing demand globally, and it's well on its way to become a blockbuster. Our second point is our project portfolio, which is progressing really well together with our BrainTransporter technology with new innovations. The third area is strong interest from potential partners. And the fourth one is that we have a strong financial position, and next week is our AGM, where there will be a decision around a dividend of two Swedish crowns per share. And we have a strong and solid financial position with more than 2 billion Swedish crowns in cash. So all in all, I think we are exceptionally well positioned for our continued growth journey, and I think the future looks very bright for biotech, and we are bringing hope for many patients. Next slide please. So by that we say thank you so much for your attention and we're happy to take some questions.

Operator
28:33 - 28:50

If you wish to ask a question. Please dial Pound Key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial Pound Key six on your telephone keypad. The next question comes from Josef Hedin from RP securities. Please go ahead.

Gunilla Osswald
28:53 - 29:36

Good morning. Thanks for taking my questions. Your Q1 R&D spend was substantially above any quarter that we saw last year. And you've highlighted the progression of the portfolio. Just wondering if you could give any color as to which individual projects are seeing the greatest increasing costs. And then if you could give us any idea of the phasing of R&D costs that you expect going through this year. And second question. Just on the Exidavnemab Phase 2 study. Can you confirm what the final number of Parkinson's disease and MSA patients were after the study was fully recruited? Thank you.

Anders Martin-Löf
29:39 - 31:00

Right. So, if we start with R&D costs, basically what happens when we start R&D enabling activities in a program, we invest a lot more in CMC. So, there are a couple of programs where we are undertaking those activities right now. In the Parkinson program, we are spending more on both antibodies and the follow-up compound that is coupled with our BrainTransporter. So I would say the alpha synuclein area is where we have increased the most. Without going into specifics regarding what program, then for the year, we expect the cost to be a little bit lumpy, going up and down. So it's not a really good estimate for the phasing of the costs during the year. So maybe it was a little bit higher than it will be in the next quarter. But it's really hard to tell. So I would just stick to the full year guidance of a 40 to 60% increase over last year in our total cost. That's the only guidance I can give you that is more accurate. And then for the other question, I think it's up to you to answer regarding the existing trial.

Gunilla Osswald
31:00 - 32:05

Yeah. Thank you for those questions. And in terms of the portfolio and the cost for R&D, of course, programs that are closer to IND and are more costly because they may initiate CMC activities and manufacturing and also toxicology studies to enable the clinical trials. So the two programs that I talked about, where we have initiated IND enabling activities, the BAN2238 and 3014 are of course more costly in our R&D portfolio in the early pipeline. And then, of course, our clinical asset is also a more costly program. And in terms of the number of patients in the study, for example, for Parkinson's, we had two cohorts with two different doses, a low dose and a high dose, with 12 patients per arm. And it actually it was 13 patients per arm. So we have those 26 patients for PD, and for MSA, we have only dosed the higher dose. So that is 12 patients that have been used in the MSA cohort.

Oskar Bosson
32:09 - 32:11

That's great. Thank you very much.

Operator
32:15 - 32:20

The next question comes from Susanne van Fort Hausen from Kempen. Please go ahead.

Oskar Bosson
32:22 - 32:54

Hi there. Thanks for taking my questions. Maybe first on the BrainTransporter. Can you elaborate how your strategic discussions have been progressing over the recent few months? And where the interest is geared more towards you at this moment? Is it in one of your existing programs, or more on the use of the technology for another pharma program, or is it more technology-based for different modalities? Some color would be nice. And then I have a follow up on Leqembi for that.

Gunilla Osswald
32:56 - 33:15

So, I think what we can say is that we have a broad interest. We have interest both for our drug programs. We also have interest in our BrainTransporter platform, including prior developments. We also have interest in the new developments we are working on. So I would say broad interest.

Oskar Bosson
33:19 - 33:35

Got it. And then on Leqembi. As for the Eisai guidance, how comfortable are you with the number that they put out? And can you elaborate a bit more on the status and next steps in the launch in the Nordic countries where you have commercialization rights? Thank you.

Anders Martin-Löf
33:37 - 33:54

As for the full-year forecast, we can't really comment on that. This is a sales forecast, and we believe that they are good at forecasting and we can't really comment any more than that. As for the Nordics, I'll turn to that.

Gunilla Osswald
33:55 - 35:03

Yes, I already alluded to in the presentation, we were obviously disappointed with the Swedish negative recommendation, as our ambition is really to help patient access to these innovative treatments. But our Nordic launch strategy is really long term and evidence driven. As we know, the reimbursement decisions differ across countries and systems all across Europe actually. And we know that it takes time in Europe generally, if you compare to the US and Asia when it comes to speedy access and new innovations. So we continue our dialogue with the different stakeholders and authorities, and as I mentioned, there might be some other pathways going forward with discussing a broader reimbursement in the different countries. So we continue to engage and prepare for a broader reimbursement. And as we know, neither Europe nor Sweden is a significant contributor to our financial expectations of revenue. So we have time and we continue.

Operator
35:13 - 35:29

As a reminder, if you wish to ask a question, please dial Pound Key five on your telephone keypad. The next question comes from Rajan Sharma from Goldman Sachs. Please go ahead.

Oskar Bosson
35:30 - 36:07

Hi. Morning. Thanks for taking my questions. So firstly on Exidavnemab. Could you just help us understand what your internal bar is for a positive readout? I guess that's another way. What would you need to see to justify further development, given that we've seen a reasonable amount of attrition with the mechanism previously? And then one on the commercial, I realize it's small, but could you just help us understand the size of the commercial opportunity for the Mab in the private markets, in the Nordic regions? Are there any sort of comps that you could point to where there have been some successful rollouts in that segment of the market? Thank you.

Anders Martin-Löf
36:12 - 37:59

Okay. So with regard to Exidavnemab, what we are looking for here, we should remind ourselves what kind of study this is. It is a study where the primary endpoint is safety and tolerability, and where we also will be looking at pharmacokinetics to see which doses should we use in Phase 2B. And we also have included some biomarkers. But they are more there in order to learn from and prepare for the next Phase 2B studies. So I think a positive readout would be that it's well-tolerated and looks safe, and that we can see what dose to use in the next study, and that we have learned how to use the biomarkers. So that is what I would expect. And I think we will have an analysis. An interim analysis for safety at an early stage. And then at the end of the year, we will have the full results from the study. And if I may add to that, in terms of recent iterations, there's also been recent progress with two alpha synuclein antibodies. Now in phase three studies, the Prasinezumab for PD from Roche and the Vakomab from Lundbeck in MSA. So and I think that every antibody needs to stand on their own merits. And we have a very, very selective and the most selective antibody for what we believe are the toxic species, the aggregated alpha synuclein. So we have a differentiated profile. We also have an excellent human PK profile with a half-life of 30 days in humans. So a combination of this high selectivity and the very attractive pharmacokinetic profile, I think enables us to really test the concept of alpha synuclein lowering in an excellent way with Exidavnemab. So I think it's very important to not mix the antibodies with each other. And the study design is also very, very different. I would say.

Gunilla Osswald
38:02 - 39:21

Yes. So in the question on the size of the private market in the Nordics, I would say it's not a huge private market in the Nordics. So you shouldn't have any major expectations on the, on the sales. But I think it differs from one country to another. And you have to remember also that of course the different authorities have set up some requirements when it comes to the risk minimisation measures required by EMA, and all four major Nordic countries have different ways of adjusting that. So it takes a little bit of time to set the clinics up and see if they kind of meet the criteria to offer treatment of Leqembi to private patients. But we think it's a good experience. And of course, it's very reassuring to know that some patients do have the opportunity at least to get treatment. And it's also much appreciated by the healthcare professionals in the other Nordic countries to hear the experience that the Finnish clinics are now having, when they are treating more and more patients in Finland. So I think it's reassuring to see that there is an interest to provide this treatment to patients. But of course, we're looking forward to a broader reimbursement.

Anders Martin-Löf
39:25 - 39:25

Thank you.

Operator
39:29 - 39:33

The next question comes from Josef Hedin from RP securities. Please go ahead.

Anders Martin-Löf
39:51 - 40:27

Sorry. Sorry about that. Just a couple of follow ups. So BAN2238 is. Is that the same antibody, just conjugated to the BrainTransporter Platform, or is it a distinct antibody? And then secondly, you talk about expanding use of the BrainTransporter Platform. So when we're thinking about incorporating different modalities, how much do you need to modify? You know, the technology itself. Is it all still based on the transferrin receptor? Are we talking about subtle tweaks or is it something larger? Thank you.

Operator
40:29 - 41:40

If I start with the first question on BAN2238, it's not the same antibody; it's a slightly modified antibody. And that's all I can say. And it's of course coupled to BrainTransporter Technology as well, but it's not Leqembi. And for the second question, in terms of modifying the BrainTransporter Platform, this is a very versatile platform. And we have different transferrin receptor binders with different affinity. So depending on what you want to achieve, if it's a large Cmax or an AUC in the brain, if you need a rapid uptake or what kind of pharmacokinetic profile you need, you might need different affinities for the transferrin receptor. So this is a family of different options that we have. And it's a very versatile platform that we can tailor-make based on the target, the indication, and the pharmacokinetic profile that you want to achieve with your specific modality and target of interest. It is very versatile, and we have modified it in several ways in order to play with it with different targets.

Gunilla Osswald
41:44 - 41:46

Okay. Thank you.

Operator
41:49 - 41:57

There are no more phone questions at this time, so I hand the conference back to the speakers for any written questions and closing comments.

Gunilla Osswald
41:58 - 42:21

Thank you so much. So we have one written question from Frederick at Redeye. And it reads: Any near-term effect on investments or costs in Sweden to be compensated for in the Leqembi co-promotion in the coming quarter due to the recent recommendation by the NT-council. Anything we can comment there?

Anders Martin-Löf
42:22 - 42:23

No.

Gunilla Osswald
42:24 - 42:25

That's the short answer.

Oskar Bosson
42:27 - 42:40

We continue to prepare and we really hope that we will be able to help Swedish patients; even though the financial impact is not large, we are still committed to assisting them.

Anders Martin-Löf
42:50 - 42:53

Operator, I see that there's somebody waiting in the speaker queue.

Operator
42:56 - 43:01

The next question comes from Natalia Webster from RBC. Please go ahead.

Anders Martin-Löf
43:20 - 43:21

We can't hear you, Natalia.

Operator
43:24 - 43:26

Apologies for that. Can you hear me? Okay. Now?

Gunilla Osswald
43:26 - 43:28

Yes, perfectly.

Oskar Bosson
43:29 - 44:07

Thank you. Firstly, just follow up on Leqembi. Regarding the sub-Q induction, PDUFA delay. Appreciate. We have Eisai's guidance for the full year, but how does a three-month delay affect your assumptions around the ramp through the year? And are there any read-throughs for the Japanese sub Q initiation timeline as well? Then the second question is just on the Brain Transporter BAN2803. You previously had plans to go into phase 1 in 2026. Appreciate it's up to BMS, but are you able to share any details around timelines there? Thank you.

Anders Martin-Löf
44:10 - 45:43

So if we start with the subcutaneous auto injector, where the FDA has a new date of 24th of August, and they have asked for some more data on switching between I.V. and subcutaneous administration. And our partner Eisai is very confident that this will run through in a good way. And we have a priority review, and even if it is a three-month delay, it's still a shorter review time than if we had had a standard review time. So, I would not be surprised if it comes before 24th of August. But that's the date, and I don't think that we should see any read through in this delay to Japan. On the other hand, we see that, as I mentioned, Q3 is when they expect that response. So I think that it all looks very good. And I think that's a subcutaneous injector, which in the US is called an auto-injector. It's a really important next step, which I think that will help patients a lot in making it more convenient. Your other question, I didn't quite hear, but I thought you asked about BAN2803, which is partnered with Bristol Myers Squibb, and it's really in their hands, and we're not commenting upon exactly when that will go into clinical development, but it's progressing well. According to the news we have.

Operator
45:46 - 45:47

Thank you.

Gunilla Osswald
45:57 - 46:16

Okay. We see there's another written question here from Eric Elgort at Carnegie. And that's regarding the recent data that came out from Biogen on their tau project, and what the implications are, if any, for the field with that.

Oskar Bosson
46:16 - 47:11

So I think what we have seen in the Alzheimer's field so far is that we have two treatments that have shown positive clinical data and also got through full registration process, Leqembi and one more. And then it is, of course, important to see if there can be other treatments coming through as well. And we saw that there are some interesting data coming out from the phase two study from Biogen. And I really look forward to seeing the results at AIC. And I think it's good that we can have combination treatments in the future. We should remember that Leqembi. Even though the target is amyloid, we also affect phospho tau and so forth. I think maybe in the future that will be good with combination treatments as well. So I really look forward to seeing what data emerges.

Anders Martin-Löf
47:20 - 47:30

There doesn't seem to be any more questions lined up for us. So with that, I think we thank everybody for listening in today. And looking forward to seeing you soon again.

Continue to the webcast
Pierce Group, Audiocast, Q3'26
Language: English11/13/2026, 8:00 AM
Göran Dahlin Good morning, everyone, and welcome to Pierce Group's presentation of our Q3 2026 interim results. Next slide, please. I am Göran Dahlin, CEO of Pierce Group, and I am with Fredrik Kjellg…
Surgical Science Sweden, Audiocast, Q3'26
Language: English11/12/2026, 10:00 AM
Tom Englund Hi everyone, and welcome to this earnings call for Surgical Science for the third quarter of 2026. My name is Tom Englund. I am the CEO. And with me today is our CFO, Anna Ahlberg. I wil…
ExpreS2ion Biotech – Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 9:00 AM
ExpreS2ion is expected to release its Q3 2026 interim report on 12 November 2026. Later the same day at 10.00, ExpreS2ion’s CEO Bent U. Frandsen and CFO Keith Alexander will present the results and answer questions in a live online event.
Meko Services AB, Q3'26
Language: English11/12/2026, 8:00 AM
Pat Thank you. Good morning, and welcome to MEKO's presentation of the third quarter of 2026. I am here with our CFO, Christy Johansson, and I will begin with an overview of the quarter and some of th…
WeSports Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Unknown 1 It. Ted Sporre Welcome to our Q3 release presentation. As you know, we have already shared preliminary figures for sales and EBITDA for this quarter, but today we complete the picture. We wi…
Nordrest Holding, Audiocast, Q3'26
Language: Swedish11/12/2026, 8:00 AM
Thomas Dahlstedt Hej och välkomna! Vi ska idag presentera Nordrests senaste kvartal och tillika resultatet för perioden. Jag som pratar nu heter Thomas Dahlstedt och är grundare och tillika VD för bol…
Karnov Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Pontus Bodelsson Welcome, everyone, to Karnov Group's earnings conference, where we will present the outcome of the third quarter of 2026. Please go to slide two. I am Pontus Bodelsson, President and…
Fasadgruppen Group, Audiocast, Q3'26
Language: English11/12/2026, 7:15 AM
Magnus Blomberg Perfect. Good morning and welcome to the Fasadgruppen presentation of our results for the third quarter 2026. My name is Magnus Blomberg. You have met me before. I am the CFO of Fasadg…
Munters AB, CMD
Language: English11/11/2026, 1:00 PM
Lena Dauvergne Good. Good afternoon everyone, and a warm welcome to Stockholm, to ESSEX and to Montage Capital Markets Day 2026. Montage Capital Markets Day 2026. It is really good to see so many of y…
Cinclus Pharma, Audiocast, Q3'26
Language: English11/11/2026, 1:00 PM
Christer Ahlberg Thank you. Hello and welcome to the Cinclus Pharma third quarter 2026 earnings call. I am Christer Ahlberg, CEO of Cinclus Pharma, and with me today is our CFO, Magnus Christensen. We…
Proact IT, CMD
Language: English11/11/2026, 12:30 PM
Unknown 1 The world of data is constantly changing. Breaches are rising, and attacks are getting more advanced. Regulation drives the need for data sovereignty. Data has to be available. Critical busi…
Ferronordic AB, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Henrik Good morning, everyone, and welcome to our presentation of the third quarter of 2026. During the quarter, we saw higher earnings, and growing aftermarket revenue was up 15% to 1.2 billion Swedi…
BICO, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Anders Fogelberg Good morning, everyone, and welcome to BICO's earnings call for the third quarter of 2026. I am Anders Fogelberg, President and CEO of BICO. And joining me today is our Group CFO, Ewa…
Catena Media, Audiocast, Q3'26
Language: English11/10/2026, 5:00 PM
Manuel Stan Good afternoon. Good evening, everyone. Welcome to the Catena Media Q3 Interim Report. I am Manuel Stan and today I'm joined by our Chief Financial Officer, Michael Gerrow. Today we will b…
Ellos Group, Q3'26
Language: English11/10/2026, 8:00 AM
Hans Ohlsson Live. Good morning, everyone, and welcome to the second presentation for Ellos Group as a listed company. We have 45 minutes today for the presentation. And there is a hard stop. After th…
Scandic Hotels Group, Audiocast, Q3'26
Language: English11/10/2026, 8:00 AM
Jens Mathisen Thank you so much, and good morning, everyone, and thank you for joining us for the Q3 presentation. I am Jens Mathisen, CEO of Scandic. And joining me is our CFO, Pierre Carstensen. We…
Svevik Industri, Q3'26
Language: Swedish11/6/2026, 9:00 AM
Johan Hårdén Tack så mycket! Hello and welcome to this hearing regarding the Q3 2026 interim report. We have an agenda where we intend to introduce ourselves to all the new shareholders as well. Kort…
Attendo, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Martin Tivéus Good morning, everyone, and thank you for joining us. Today, we will present our results for the third quarter of 2026. I am pleased to announce that this is the strongest quarter for At…
Cavotec, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
David Pagels Good morning and welcome to Cavotec's Q3 2026 presentation. I am David Pagels, the CEO of Cavotec. And together with me today, I have our new CFO, Christoffer Robertsson. I would like to…
Fractal Gaming Group, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Jonas Good morning, everyone, and welcome to Fractal's Q3 2026 presentation. Today, we'll take you through our results, the progress that we've made, and our priorities ahead after a difficult first h…